NCT05212103 (CANSI) is a clinical trial in Acute Myeloid Leukemia, sponsored by Turku University Hospital.

Who is sponsoring NCT05212103?

NCT05212103 is sponsored by Turku University Hospital.

What condition does NCT05212103 study?

NCT05212103 studies Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer.

Is NCT05212103 still recruiting?

NCT05212103 is currently enrolling by invitation. Last updated 4 December 2024.

Last reviewed 2024-12-04 · How we verify

NCT05212103: CANSI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9

ENROLLING BY INVITATION Last updated 4 December 2024

What this trial tests

trial in Acute Myeloid Leukemia in 30 participants. Enrolling by invitation.

Timeline

1 September 2023

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Turku University Hospital
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 September 2023
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Finland

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Melanoma — all drugs for Melanoma →
Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Turku University Hospital

Who can join

Adults 18 to 100, any sex, with Acute Myeloid Leukemia or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [<sup>68</sup>Ga]Ga-DOTA-Siglec-9.
Dadson P, Ylä-Outinen H, Kalliokoski K, Tuokkola T, et al · · 2025 · PMID 41420234 · DOI 10.1186/s12931-025-03455-8

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Turku University Hospital trials

Trials by the same sponsor.

NCT07488494 — Effective Implementation of the Physical Activity and Motor Skills Intervention for 3-6-year-old Children With Cancer (E · NA · not yet recruiting
NCT07316868 — Neuroprotective Effect of Mild Hypothermia Versus Normothermia During Cardiopulmonary Bypass of Coronary Artery Surgery · NA · not yet recruiting
NCT07306000 — Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development · NA · recruiting
NCT07272824 — Usability Study of Gestational and Postpartum Weight Management Program · recruiting
NCT07310472 — Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05212103 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Turku University Hospital
Last refreshed: 4 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05212103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing